Vulval cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vulval cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nivolumab-and-imiquimod-in-adults-with-vulvar-squamous-cell-carcinoma/ Wed, 29 Apr 2026 15:10:06 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-nivolumab-and-imiquimod-in-adults-with-vulvar-squamous-cell-carcinoma/ This study focuses on patients with Vulvar Squamous Cell Carcinoma, which is a type of cancer that starts in the thin, flat cells found on the surface of the vulva. The purpose of the study is to evaluate the safety and effectiveness of combining two different medications, nivolumab and imiquimod, for this condition. Nivolumab is a drug administered through an intravenous infusion, which means it is delivered directly into a vein, while imiquimod is a cream applied to the skin.

Participants in the study will receive these treatments to see how well the combination works in treating the cancer before surgery. The study is divided into two parts. The first part focuses on monitoring for any side effects or safety concerns caused by the medications. The second part looks at how well the combination of drugs reduces the cancer cells.

]]> Study of pembrolizumab and lenvatinib treatment for patients with vulvar cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-treatment-for-patients-with-vulvar-cancer/ Wed, 29 Apr 2026 15:07:19 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-treatment-for-patients-with-vulvar-cancer/ This clinical trial focuses on patients with vulvar cancer, a type of cancer that develops in the external part of the female reproductive organs. The study will test a combination of two medications: Pembrolizumab (also known as KEYTRUDA), which is given through an intravenous infusion, and Lenvatinib, which is taken as an oral capsule. The purpose of this research is to determine how well these medications work together and how safe they are for treating vulvar cancer patients.

The study is designed for different groups of patients with vulvar cancer: those with tumors that cannot be removed by surgery, those who have never received chemotherapy for their recurrent or spreading cancer, and those whose cancer has returned after previous treatment or has spread despite chemotherapy. The treatment involves receiving both medications – Pembrolizumab through an infusion into a vein and Lenvatinib as daily capsules.

During the study, doctors will monitor how the cancer responds to the treatment combination and watch for any side effects. Patients will have regular check-ups and medical tests to evaluate their health status. The medication doses are carefully determined – Pembrolizumab will be given at 200 mg through infusion, while Lenvatinib will be given at 20 mg daily in capsule form.

]]> Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-vulvar-cancer-not-suitable-for-surgery-or-radiotherapy/ Wed, 29 Apr 2026 15:03:01 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-vulvar-cancer-not-suitable-for-surgery-or-radiotherapy/ This clinical trial is focused on studying a type of cancer called vulvar cancer, which affects the external part of the female genital organs. The study is specifically for cases where the cancer has come back, is persistent, has spread to other parts of the body, or is locally advanced and cannot be treated with surgery or radiation to cure it. The trial will use a combination of two medications: Pembrolizumab and Lenvatinib. Pembrolizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while Lenvatinib is taken orally in the form of capsules.

The purpose of this study is to evaluate how effective the combination of Pembrolizumab and Lenvatinib is in treating vulvar cancer. Participants in the study will receive these medications and will be monitored to see how their cancer responds to the treatment. The study will look at how many patients experience a reduction in their cancer size or complete disappearance of the cancer within 24 weeks of starting the treatment. The study will also assess the overall health and quality of life of the participants during the trial.

Throughout the study, participants will be regularly checked by healthcare professionals to monitor their response to the treatment and any side effects they may experience. The trial aims to provide valuable information on the effectiveness of this treatment combination for vulvar cancer, which could help improve future treatment options for patients with this condition.

]]> Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-vulvar-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:59:42 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-for-patients-with-vulvar-squamous-cell-carcinoma/ This clinical trial is focused on studying vulvar squamous cell carcinoma, a type of cancer that affects the vulva. The treatment being tested is called pembrolizumab, which is also known by its brand name, KEYTRUDA. Pembrolizumab is a medication that is given through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to explore how effective pembrolizumab is when used before surgery to reduce the size of the tumor.

Participants in the study will receive pembrolizumab and will be monitored to see how the tumor responds to the treatment. The study will also look at how the body’s immune cells, specifically a type of cell called effector T cells, react to the treatment. These cells are part of the immune system and help fight cancer. The study will last for several weeks, with the first assessment of the tumor size taking place approximately six weeks after the first dose of pembrolizumab.

The trial aims to gather information on the safety and effectiveness of pembrolizumab in treating vulvar squamous cell carcinoma. Researchers will also observe any changes in the tumor and the behavior of immune cells during the treatment. This study is an important step in understanding how pembrolizumab can be used to help patients with this type of cancer.

]]> Study on the Safety of Using Chemoradiation with Cisplatin and Carboplatin for Early-Stage Vulvar Cancer Patients with Macrometastasis in Sentinel Lymph Node https://clinicaltrials.eu/trial/study-on-the-safety-of-using-chemoradiation-with-cisplatin-and-carboplatin-for-early-stage-vulvar-cancer-patients-with-macrometastasis-in-sentinel-lymph-node/ Wed, 29 Apr 2026 14:47:51 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-using-chemoradiation-with-cisplatin-and-carboplatin-for-early-stage-vulvar-cancer-patients-with-macrometastasis-in-sentinel-lymph-node/ This clinical trial is focused on studying vulvar cancer, a type of cancer that affects the external female genitalia. The trial is investigating the safety of using a combination of chemotherapy and radiation therapy, known as chemoradiation, as a treatment for early-stage vulvar cancer. The study aims to see if chemoradiation can safely replace a more invasive surgical procedure called inguinofemoral lymphadenectomy, which involves removing lymph nodes in the groin area. This approach is being tested in patients who have a macrometastasis, which means a cancer spread larger than 2mm, in the sentinel lymph node, a key lymph node that cancer cells are likely to spread to first.

The trial involves the use of two chemotherapy drugs: cisplatin and carboplatin. These drugs are given as a solution through an intravenous (IV) infusion, which means they are delivered directly into the bloodstream through a vein. The study will observe patients over a period to monitor the safety and effectiveness of this treatment approach. The main goal is to see if this method can prevent the recurrence of cancer in the groin area, while also looking at other factors such as treatment-related side effects, survival specific to the disease, and the quality of life reported by patients.

The trial is expected to continue until March 2029, with the recruitment of participants having started in July 2019. By participating in this study, researchers hope to gather important information that could lead to less invasive treatment options for patients with early-stage vulvar cancer, potentially improving their overall treatment experience and outcomes.

]]> Study of TG4001 and Avelumab for Patients with Advanced HPV-16 Positive Cancers https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ This clinical trial is focused on studying certain types of cancers that are linked to a virus called Human Papillomavirus (HPV), specifically the type known as HPV-16. The cancers being studied include those that can occur in areas such as the head and neck, cervix, vulva, vagina, penis, and anus. The study is testing a combination of two treatments: avelumab, which is a type of cancer immunotherapy, and TG4001, which is another form of immunotherapy designed to help the body’s immune system fight cancer cells.

The purpose of the study is to evaluate how safe and effective these treatments are when used together in patients with advanced stages of these HPV-16 related cancers. The study will be conducted in two phases. In the first phase, the focus will be on understanding the safety and how well patients tolerate the combination of avelumab and TG4001. In the second phase, the study will look at how well the combination works in terms of slowing down the progression of the cancer compared to using avelumab alone.

Participants in the study will receive the treatments through injections or infusions, and their health will be monitored over time to see how the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of treatments can offer a new option for patients with these types of cancers.

]]> Study Comparing Chemoradiation and Chemotherapy with Cisplatin, Paclitaxel, and Carboplatin for Patients with Advanced Vulvar Cancer https://clinicaltrials.eu/trial/study-comparing-chemoradiation-and-chemotherapy-with-cisplatin-paclitaxel-and-carboplatin-for-patients-with-advanced-vulvar-cancer/ Wed, 29 Apr 2026 14:23:37 +0000 https://clinicaltrials.eu/trial/study-comparing-chemoradiation-and-chemotherapy-with-cisplatin-paclitaxel-and-carboplatin-for-patients-with-advanced-vulvar-cancer/ This clinical trial is focused on studying the treatment of locally advanced vulvar carcinoma, a type of cancer that affects the external female genital organs. The study aims to compare two treatment strategies: primary chemoradiation and neoadjuvant chemotherapy followed by surgery. Chemoradiation combines chemotherapy and radiation therapy to target cancer cells, while neoadjuvant chemotherapy involves administering chemotherapy before surgery to shrink the tumor.

The medications being used in this study include cisplatin, paclitaxel, and carboplatin. These are chemotherapy drugs that help stop the growth of cancer cells. Cisplatin and carboplatin are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Paclitaxel is also given in the same way. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

The purpose of the study is to evaluate the effectiveness and safety of these treatment strategies in patients with locally advanced vulvar carcinoma. Participants will undergo treatment over a period of several months, with regular monitoring to assess their response to the treatment and any side effects. The study will also look at factors such as quality of life, organ preservation, and the influence of HPV status on treatment outcomes. The trial is expected to continue until 2029, with the goal of improving treatment options for this type of cancer.

]]>